Levels of and changes in psychosis symptoms and clinical insight: Exploring the impact of differential antipsychotic mechanisms

Read full text
Authors: Lena Antonsen Stabell, Erik Johnsen, Rune A. Kroken, Else-Marie Løberg, Eirik Kjelby, Inge Joa, Solveig Klæbo Reitan, Maria Rettenbacher, Kenneth Hugdahl, Rolf Gjestad
Cited by: 2
References: 53

Abstract

• Symptom reduction is paramount to increase insight • This study provides details on specific symptom factors’ influence on insight • Change in positive symptoms influenced insight fastest • No differences between antipsychotic naïve patients and those previously medicated • This study provides preliminary evidence that DAs may improve insight more than the PDA aripiprazole, but uncertainty remains. Impaired clinical insight is common in schizophrenia spectrum disorders (SSDs) and predicts poor treatment adherence and outcomes. It is linked to disorganised, positive, negative, and hostility symptoms. However, few studies repeatedly assess insight after antipsychotic initiation while comparing pharmacologically distinct agents. This study examined how symptom levels and changes predict the development and endpoint of clinical insight over 6 weeks, contrasting the partial dopamine agonist aripiprazole (PDA) with two dopamine antagonists (DAs). Data from 144 SSD patients in the Bergen-Stavanger-Innsbruck-Trondheim (BeSt InTro) trial, a pragmatic, semi-randomised study of amisulpride, aripiprazole, and olanzapine, were analysed using latent growth curve models. Insight was measured by PANSS Item G12; symptom factors (positive, negative, hostility, cognitive/disorganised) were derived from PANSS. Lower baseline symptoms and greater improvement between weeks 3 and 6 predicted better insight at 6 weeks across all factors. For positive symptoms, improvement between weeks 1 and 3 (b = 0.57, p = 0.009) also predicted better insight. Patients on aripiprazole showed less improvement in insight, though some findings lost significance after correction. Symptom reduction is associated with improved insight, with early changes in positive symptoms exerting the fastest effect. Despite symptom improvement, aripiprazole PDA treatment was linked to less insight gain than DA treatment. These preliminary findings warrant further study.

Fields of Study & Subjects

Schizophrenia research and treatment Treatment of Major Depression Bipolar Disorder and Treatment

Publication details

Journal / source
Psychiatry Research
Publisher
Elsevier BV
Volume
358
Pages
116948–116948
Publication date
9 January 2026
Language
EN